HCW Biologics Inc. reported on February 26, 2026, that Nasdaq confirmed it regained compliance with all listing rules after a review by the Hearings Panel, following an extension granted on October 13, 2025. The company must now adhere to ongoing monitoring for a year to maintain its listing.